Sweden's Isofol Medical Q1 net loss widens, raises funds

Isofol Medical AB (publ)

19/05/2026 07:09

Overview

Sweden biotech firm reported no Q1 revenue and a wider net loss yr/yr

Company raised SEK 18.9 mln from warrant exercise to reinforce financial position

Patient recruitment in phase Ib/II study slower than expected; regulatory approval granted to expand centers

Outlook

Company aims to accelerate patient recruitment by adding at least one new study center

Isofol expects broadened inclusion criteria to enable direct comparison with leucovorin

Company sees regulatory approval supporting expansion of ongoing phase Ib/II study

Result Drivers

SLOW PATIENT RECRUITMENT - Company said patient recruitment in its phase Ib/II study was slower than expected, prompting regulatory approval to add study centers

WARRANT EXERCISE - Company raised SEK 18.9 mln from exercise of series TO1 warrants and guarantee commitments

Company press release: ID:nMFN25NSKl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 0
Q1 EPS
-SEK 0.05


Analyst Coverage

Wall Street's median 12-month price target for Isofol Medical AB (publ) is SEK1.90, about 149% above its May 18 closing price of SEK0.76

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)